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Abstract. Severe childhood malarial anemia is commonly treated using blood transfusion. Although transfusion
may decrease short-term mortality, the risk of human immunodeficiency virus (HIV) transmission is considerable in
Africa. We constructed a decision tree to weigh the short-term mortality benefit of transfusion against HIV infection
risk. Probability estimates were derived from published studies. The base-case was a two-year-old child with a 13.5%
mortality risk to be transfused with screened or unscreened blood (1% or 13% HIV contamination risk, respectively),
with reduction of mortality to 5.5% by transfusion (odds ratio 5 2.7), and a 2.4% risk of fatal transfusion compli-
cations. A sensitivity analysis was performed to assess the influence of variation in these estimates. If a child devel-
oped acquired immunodeficiency syndrome, survival was weighed as one-tenth of normal survival. For the base-case,
we found that transfusion with screened blood provided a survival benefit of 5%. In contrast, transfusion with
unscreened blood decreased survival by 2%. Patients with a mortality risk , 5% derived no benefit from a transfusion
with screened blood. Other important factors for the benefit of transfusion were the effectiveness of transfusion in
reducing mortality and the risk of blood contamination. A blood transfusion was clearly beneficial if the mortality
risk was high and the risk of contamination was low. Our findings can be used as a basis for a clinical transfusion
policy that limits transfusions to situations in which they are likely to be beneficial. This will in turn optimize child
survival and prevent unnecessary exposure of low risk children to the transfusion risks.
With the risk of transmission of the human immunodefi-
ciency virus type-1 (HIV-1), the use of blood transfusion in
the management of severe pediatric anemia has become an
important clinical decision problem in Africa.1,2 Severe ma-
laria-associated pediatric anemia increasingly is a major
cause of hospital admission and death as the spread of chlo-
roquine-resistant Plasmodium falciparum malaria intensifies
across the continent.3–6 Subsequently, the demand for blood
transfusions has increased. In some settings, 20–50% of the
hospitalized children were transfused.7,8
The prevalence of HIV infection among blood donors has
increased in most developing countries, and at least 10% of
all African pediatric acquired immunodeficiency syndrome
(AIDS) cases may have arisen from contaminated blood
transfusions.2,9–11 Many African countries, particularly where
P. falciparum malaria is endemic and HIV/AIDS is a major
health issue, cannot maintain an adequate blood supply, and
fail to screen all their donated blood.11–14 Even screened
blood can be infectious, with a risk that depends on the back-
ground seroprevalence among the blood donors and on the
quality of the screening.12,15
The mortality from severe anemia is known to be higher
with more intense P. falciparum transmission patterns and
patient characteristics such as younger age, lower hemoglo-
bin level, and presence of respiratory distress or impaired
consciousness.7,16–22 A survival benefit of transfusion was
found in an observational study in western Kenya,7 but the
effectiveness of transfusions has unfortunately not been stud-
ied in randomized controlled trials.
In this study, we examined when administration of a blood
transfusion is beneficial, using decision analysis as a frame-
work for synthesis of the available evidence.23 We weigh the
risks of mortality with severe anemia against complications
and HIV risks associated with receiving a blood transfusion.
This understanding will enable clinicians to perform in-
formed risk-benefit evaluations prior to making any trans-
fusion decisions.
METHODS
Model structure and assumptions. A decision analysis
model was constructed for the problem of whether or not to
transfuse a severely anemic child less than five years of age
with an acute P. falciparum malaria infection. Severe ma-
larial anemia was defined as a hemoglobin level , 5 g/dL
and any level of peripheral malaria parasitemia. We struc-
tured the problem similar to a previously published decision
tree (Figure 1).24
Depending on the clinical presentation, the attending phy-
sician in consultation with the accompanying guardian de-
cides on the need for a transfusion. When the strategy ‘‘Do
not transfuse’’ is chosen, the patient may die of the patho-
logic processes associated with anemia and/or malaria, or
survive the acute phase of the disease. For transfusion, a
blood unit is selected or a donor sought. In the short-term,
the recipients may die of anemia, malaria, or non-HIV trans-
fusion complications. The selected blood unit may be HIV
contaminated. Even if screened, this status cannot usually be
known with certainty, specifically due to laboratory error,
limits in test sensitivity, or window period (time between
infection and detection of antibodies to HIV).15 Surviving
patients may acquire HIV infection and develop AIDS.
Treatment outcomes considered in this analysis were surviv-
al, death, or survival with AIDS.
In structuring this problem, we made a number of as-
sumptions. We assumed that the decision to transfuse means
immediate transfusion. In practice, the decision may take the
form of either an immediate transfusion or one after a period
of patient observation during which the patient’s state is
monitored for deterioration. Second, the effectiveness of a
transfusion is assumed to be equal for patients risking death
from anemia and patients risking death from malaria (par-
ticularly cerebral malaria). This may be reasonable since
most of the risk factors overlap (e.g., impaired consciousness
and respiratory distress).16 Third, we assumed that the pa-
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FIGURE 1. Transfusion decision tree. O represents a chance node, and M represents a decision node. p indicates the probability of occurrence
of an event, as used in the base-case analysis. The numbers enclosed in square boxes at the terminal nodes are the valuations for the outcomes.
AIDS 5 acquired immunodeficiency syndrome.
TABLE 1
Severe malarial anemia mortality studies in Africa, 1990–1997
First author, year N Deaths (%)
Transmission
pattern
Lackritz, 19927
Brewster, 199318
Craighead, 199326
Holzer, 199327
684
1,050
155
105
125
101
15
3
(18.3)
(9.6)
(9.7)
(2.9)
High
Low
Moderate
Moderate
Slutsker, 19946
Marsh, 199516
Zucker, 199619
Newton, 199728
Total
910
506
126
46
3,582
140
25
14
4
427
(15.3)
(4.9)
(11.1)
(8.7)
(11.9)
Moderate
Low
High
Low
tients had no HIV infection before treatment. Finally, we
assumed that an effective antimalarial drug (e.g., quinine)
had already been administered.
Model quantification. Probabilities of the occurrence of
the different events in the decision analysis were based on
published studies as identified with a MEDLINE search.
Plausible ranges were defined for the probabilities, based on
95% confidence intervals (CIs) or ranges found in the lit-
erature.
To determine when the benefits of transfusion outweighed
the risks, we assumed that short-term mortality was the
worst outcome (valued as 0), and survival without AIDS the
best (valued as 1). Young children may develop AIDS within
two years and 50% may have died 5 five years later.25 We
therefore estimated that children with HIV and seroconver-
sion to AIDS may have a life expectancy of approximately
one-tenth the normal life-expectancy among African chil-
dren.25 The outcome AIDS was valued as 0.1, with a plau-
sible range from 0, when AIDS is considered as bad as short-
term mortality, to 0.2, when AIDS is regarded as equivalent
to one-fifth of normal survival.
A sensitivity analysis was performed to gain insight in the
effects of variation in the estimates on the difference be-
tween survival with or without transfusion. Calculations
were performed with the DATA 3.0 (TreeAge Software, Inc.,
Williamstown, MA) computer package.
RESULTS
A base-case patient was defined as a two-year-old boy
with a hemoglobin level , 5 g/dL and an acute P. falcipa-
rum malaria infection. The probabilities that were used as
estimates for this base-case patient are shown in the decision
tree (Figure 1).
Risk of in-hospital mortality with severe malarial ane-
mia. We identified eight prospective hospital-based studies
conducted in African settings that had reported mortality
rates associated with severe malarial anemia between 1990
and 19976,7,16,18,19,26–28 (Table 1). The average risk of mortality
was 12%, but the heterogeneity was significant (P , 0.001,
by chi-square test). When the studies were classified accord-
ing to the local malaria transmission level, we observed that
children residing in high transmission regions experienced
the highest mortality rates (139 [17.2%] of 810 died), fol-
lowed by moderate and low transmission areas (158 [13.5%]
of 1,170 died and 130 [8.1%] of 1,602 died, respectively).
This distinction according to transmission pattern explained
a large proportion of the heterogeneity between the studies.
However, differences between studies from low and mod-
erate transmission areas were still statistically significant (P
, 0.05, by chi-square tests). Furthermore, the case mix in
these studies included both children who received transfu-
sions and others who did not. The actual mortality risk may
thus be higher for those who were not transfused.
In any specific malaria-endemic region, individual risks of
mortality may vary considerably depending on the clinical
presentation of the patient. For instance, hospitalized chil-
dren on the Kenyan coast, who had severe anemia with re-
spiratory distress, impaired consciousness, or both experi-
enced 16%, 8%, and 36% mortality rates, respectively.16 The
mortality rate used for the decision model was 13.5 % for
the base-case (intermediate transmission region), with a
range from 3% to 30%.
Transfusion benefits and risks. The beneficial effect of
a transfusion on in-hospital mortality was derived from a
study in western Kenya. The observed odds ratio for in-
hospital mortality, hereafter referred to as transfusion effec-
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TABLE 2
Probability estimates and plausible ranges used in the decision analysis*
Variable
Baseline
estimate†
Plausible range
(%) References
Mortality from untreated anemia
(moderate transmission level)
Transfusion effectiveness (odds ratio)
HIV contamination risk
13.5%
2.7
3–30
1.9–3.7‡
see Table 1
7
Screened blood
Unscreened blood
1.0%
13.4% 0.5–20
9,29
Probability of HIV seroconversion
Probability of AIDS development
Acute fatal complications risk
90%
80%
2.4%
90–96
78–95
1–4‡
30,31
32
11
* HIV 5 human immunodeficiency virus; AIDS 5 acquired immunodeficiency syndrome.
† Values used in calculations for the base-case.
‡ 95% confidence intervals.
TABLE 3
Eight possible scenarios based on combinations of low (L) and high (H) plausible values for the HIV contamination risk in transfused blood,
the anemia mortality risk, and the transfusion effectiveness*
Scenario
1 2 3 4 5 6 7 8
HIV contamination
L: 0.5%; H: 20%
Anemia mortality risk
L: 3%; H: 30%
Transfusion effectiveness
L: OR 5 1.9; H: OR 5 3.7
Survival differences (%)†
(transfusion-no transfusion)
H
L
L
213.4
H
L
H
212.8
H
H
L
20.7
H
H
H
16.1
L
L
L
21.3
L
L
H
20.5
L
H
L
19.4
L
H
H
117.2
* HIV 5 human immunodeficiency virus; OR 5 odds ratio.
† Positive values indicate that transfusion is the preferred strategy.
tiveness, was 2.7 (95% CI 5 1.9–3.7).7 This means that the
mortality odds with transfusion was 2.7 times lower than the
mortality odds without a transfusion.
When the transfused blood is unscreened, the probability
that it is HIV contaminated depends on the seroprevalence
levels among the donor population. The probability that a
screened unit of blood is HIV contaminated has been esti-
mated at between 0.5% and 1% in Cote d’Ivoire, where HIV
prevalence among blood donors was 11%.29 These risks were
2.1% for screened blood (Lackritz EM and others, unpub-
lished data) and 13.4% for HIV prevalence9 in western Ke-
nya. The plausible range for the probability of receiving HIV
contaminated blood was set as 0.5–20%. The probability that
seroconversion occurs after receipt of HIV-contaminated
blood has been found to be 90% in the United States30 and
96% in Zaire.31 The probability of developing AIDS after
seroconversion is approximately 80%.32 A 2.4% incidence
of fatal acute transfusion complications was observed among
transfused children in Kinshasa, Zaire.11 Table 2 summarizes
the estimates and plausible ranges used in the decision anal-
ysis.
Transfusion decisions. When we evaluated the deci-
sion tree for the base-case patient, transfusion with
screened blood led to a 7.7% risk of in-hospital mortality
and 0.7 % risk of acquiring AIDS, compared with a 13.5%
mortality without transfusion. The survival benefit was
5.2%. If the blood was not screened, we expected an 8.9%
risk of acquiring AIDS, and the survival with transfusion
was lower than without (84.3% versus 86.5%). We further
varied each estimate over its plausible range. Three fac-
tors strongly influenced the benefit of transfusion: the
blood contamination risk, the baseline mortality risk, and
the transfusion effectiveness. For the base case, transfu-
sion was the optimal decision provided that either the
blood contamination risk was , 10%, the transfusion-re-
duced mortality had an odds ratio . 1.3, or the baseline
risk of mortality was . 5%. A minimal influence on the
transfusion decision was noted for the valuation of AIDS,
or the risks of fatal complications, seroconversion to HIV
infection, or development of AIDS; for these estimates,
variation over the plausible ranges exerted a maximal sur-
vival difference of 1%.
We examined eight possible scenarios based on all com-
binations of low and high values of the three most important
factors. Table 3 shows that a transfusion is clearly beneficial
if the baseline mortality risk is high and the blood contam-
ination risks are low. A net benefit is also expected if all
three factors are on their high values (scenario 4). In the
other scenarios, transfusion leads to a lower survival. For
instance, transfusion is not indicated for a severely anemic
child with a low risk of mortality, especially if only
unscreened blood is available.
Finally, we varied the risks of blood contamination, the
baseline mortality risk and the transfusion effectiveness in
a three-way sensitivity analysis (Figure 2). The graph
shows that for three levels of transfusion effectiveness,
blood transfusion leads to a larger benefit in survival if
the mortality risk is higher and the contamination risk is
lower. Also, at a constant blood contamination risk, the
threshold (mortality risk) above which one would trans-
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FIGURE 2. Three-way sensitivity analysis for survival with or
without blood transfusion. The lines represent the combinations of
mortality risk and human immunodeficiency virus contamination
risk where survival with or without transfusion is equal for three
estimates of the effectiveness of transfusion (mortality odds ratios
[ORs] 5 1.9, 2.7, and 3.7). To the right of each line, survival with
a transfusion is higher than without one.
fuse decreases with increasing transfusion effectiveness.
Overall, we note that transfusion does not carry a survival
benefit when HIV contamination risk is high.
DISCUSSION
In this analysis we examined when it is beneficial to ad-
minister a blood transfusion to African children with severe
malarial anemia. Three factors were found to have a major
impact on this decision: the risk of mortality without a trans-
fusion, HIV contamination risk of the blood products, and
the effectiveness of a transfusion in reducing mortality.
We estimated the average risk of mortality with severe
malarial anemia to be approximately 12%, but this figure
varied considerably across reported studies. The heteroge-
neity between studies was partly explained by differences in
the intensity of malaria transmission patterns.21,33 Further-
more, the mortality risk may vary depending on several clin-
ical characteristics, such as respiratory distress, impaired
consciousness, age, hemoglobin level, parasite density, and
comorbidity.7,16–22 Transfusion was not beneficial when the
patient’s risk of mortality without a transfusion was , 5%.
Because most deaths among severely anemic children tend
to occur within 12 hr of admission, it is important to identify
those patients at high risk timely to allow for early inter-
vention. When transfusion is delayed, the child already sur-
vived the immediate period and the remaining mortality risk
will be lower.
The effectiveness of blood transfusion has been found to
be higher with a higher patient-specific mortality risk and an
early administration of the transfusion.7 Decision making
shortly after admission of the patient is thus required. This
may best be achieved with the availability of a blood bank
with screened blood. In clinical practice, the estimate of a
reduction of the mortality with an odds ratio of 2.7 may be
a starting point, while the impact of other assumptions of
effectiveness can be explored in Figure 2. Randomized clin-
ical trials are desired to provide further evidence on the ben-
efits and risks of transfusion. Such studies might be consid-
ered for children with a moderate mortality risk, e.g., ap-
proximately 5–10%, since the benefit of a transfusion is un-
clear for these children. However, the definition of this risk
group may be difficult, and the conclusions might have lim-
ited generalizability.
As expected, the likelihood of blood contamination with
the HIV-1 virus had a crucial influence on the benefit of a
transfusion. African children less than five years of age with
acute malarial anemia or sickle cell anemia are the most
frequent recipients of blood transfusions. For instance, at one
hospital in western Kenya, children received 67% of all the
administered transfusions.7 With the increasing prevalence of
pediatric malaria-associated anemia, blood screening is
therefore a priority child survival issue.34 Most African
countries have a policy of pretransfusional blood screening,
which may, however, be difficult to achieve in practice due
to logistic and technical limitations. It has been observed
that HIV contamination may be up to five times higher
among units donated for replacement or by family members
compared with banked blood from volunteer donors. More-
over, only banked blood will be available early during hos-
pitalization, when transfusion may be most effective to in-
crease survival.7,9 Because of the increasing HIV prevalence
among blood donors in most African settings, safe blood has
become a scarce and costly resource. It was estimated to cost
$14 to remove one HIV-contaminated unit by blood screen-
ing in Kenya (Lackritz EM and others, unpublished data).
Our analysis shows that using screened blood implies a sub-
stantial benefit compared with using unscreened blood (sur-
vival 1 5% versus 22%). Therefore, it may be expected that
the cost-effectiveness of blood screening is favorable in the
context of transfusion of severe malaria-related anemia in
African children. Our analysis indicates that unscreened
blood should only be given in life-saving situations. This
finding supports current transfusion policies that generally
discourage the use of unscreened blood. We recommend
continued intensification of efforts to ensure a safe blood
supply by screening and recruitment of low-risk donors.
Although this analysis was undertaken on a number of
assumptions, it has enabled us to study important consider-
ations relating to when a transfusion may be beneficial. The
methodology that we adopted can be used to study other
transfusion-transmissible infections, such as hepatitis B and
C. The results shown in Figure 2 may be applicable in all
settings in which malarial anemia and transfusion-transmit-
ted HIV-1 are important health problems. We note, however,
that the specific probability estimates used in our analysis
mainly originate from anglophone Africa, which may not be
representative for all of Africa. Furthermore, this analysis
did not consider the many nonclinical factors that trigger and
influence the clinical decision to order transfusions. These
may include the health-care provider’s perception and tol-
erance of risk, peer-pressure, and the availability of
blood.35,36
In conclusion, our study has provided a quantitative in-
sight in the relevant considerations for making transfusion
decisions in African children with severe malaria-related
anemia. This insight may support the development of clinical
transfusion policies at a local level such that transfusions be
limited to situations where they are likely to be beneficial.
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